Singapore Says One-Third of U.S. Exports Hit by New 12.5% Tariff 
Oil Prices Surge as Iran Hormuz Restrictions Renew Supply Fears 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Gold Price Hits Seven-Week High as Fed Rate Hike Bets Fade and Hormuz Deal Hopes Grow 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Brazil Cuts Selic Rate to 14% as Inflation Eases but Risks Persist 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
China Trade Surplus Beats Forecasts in July as Exports Stay Strong 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Oil Prices Set for Steep Weekly Losses as Hormuz Deal Stalls 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
US Dollar Falls as Weak July Jobs Report Dents Fed Rate Hike Bets 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
An Abbott Laboratories processing plant in Sturgis, Mich being investigated for cases of infant illness is being allowed to release some product that was processed before it was shut down.
Certain goods designed for infants and people with specific medical issues will be given out for free.
Abbott officials claimed they're doing it at the FDA's request to help with shortages of these specialty feeding items.
After a recall of Similac infant formula and other products in February, the Sturgis plant was forced to shut down. Cronobacter bacteria had infected many infants, one of whom died; cronobacter was identified in their systems and the formula they had drunk. Cronobacter bacteria were discovered in the factory during an inspection.
However, further examination revealed that the cronobacter strain that caused the infections was not the same as the one detected in the plant and that no food-contact surfaces had been contaminated.
On a case-by-case basis, Abbott is issuing cases of a nutrition supplement for people with uncommon metabolic diseases and others. The corporation stated that it is doing so at the FDA's request to assist reduce shortages.
